RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src

Overexpression of EGFR is commonly seen in gastric cancer (GC). However, patients with GC show resistance to anti-EGFR treatments. RAS mutations are rare in GC and cannot explain de novo resistance to EGFR treatments. Therefore, it is particularly important to explore the mechanisms of resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaomeng, Song, Yongxi, Song, Na, Zhang, Ye, Zhang, Lingyun, Wang, Yan, Wang, Zhenning, Qu, Xiujuan, Liu, Yunpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5229171/
https://www.ncbi.nlm.nih.gov/pubmed/28123301
http://dx.doi.org/10.2147/OTT.S110918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5229171/
https://www.ncbi.nlm.nih.gov/pubmed/28123301
http://dx.doi.org/10.2147/OTT.S110918

Ejemplares similares